Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib and Capecitabine with Radiation in Rectal Cancer
NCT00081224Phase 2Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2004
- Primary completion
- Feb 2006
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in rectal adenocarcinoma, sponsored by Cancer and Leukemia Group B. Primary endpoint: Pathological Complete Response Rate up to 5 years. Started Dec 2004; status: terminated.
02
Drugs
celecoxib
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT00081224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081224.